Where Will Vertex Pharmaceuticals Be in 5 Years?
Vertex Pharmaceuticals (NASDAQ: VRTX) is the blueprint for a growing pharmaceutical stock. Since it went public in 1991, the company has consistently increased revenue, recording annual revenue gains the past six consecutive years.
The stock's share is up more than 23% year to date thanks to its profitable stable of cystic fibrosis drugs, led by blockbuster Trikafta.
Cystic fibrosis (CF) is a progressive genetic disorder that causes lung infections, limits patients' ability to breathe, and can affect other organs. According to the Cystic Fibrosis Foundation Patient Registry, there are roughly 35,000 people in the United States and 70,000 people worldwide with CF. The average person with the disease only lives 47 years, according to the foundation's 2018 patient registry annual report.
Source Fool.com
